通过抑制临床相关人类分离株的淀粉利用系统实现非致死性生长抑制 。 （原文句子似乎不完整，“of”后面缺少具体内容）
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of .
作者信息
Santilli Anthony D, Russell Jordan T, Triplett Eric W, Whitehead Kristi J, Whitehead Daniel C
机构信息
Department of Chemistry , Clemson University , Clemson , SC 29631 , USA . Email:
Department of Microbiology and Cell Science , University of Florida , Gainesville , FL 32611 , USA.
出版信息
Medchemcomm. 2019 Jul 5;10(11):1875-1880. doi: 10.1039/c9md00301k. eCollection 2019 Nov 1.
Abstract
We describe the inhibition of the starch utilization system (Sus) belonging to various strains of in a non-lethal manner using the small molecule probe, acarbose. Concentrations of acarbose as low as 5 μM significantly impede the growth of and increase the doubling time of cultures. The successful inhibition of this species of is relevant to several disease states including type I diabetes mellitus. This method continues to explore a new, potential route to intervene in illnesses associated with aberrant changes in the composition of the human gut microbiota through the strategic manipulation of its constituents.
摘要
我们描述了使用小分子探针阿卡波糖以非致死方式抑制属于各种菌株的淀粉利用系统（Sus）。低至5μM的阿卡波糖浓度会显著阻碍菌株的生长并延长培养物的倍增时间。成功抑制这种菌株与包括I型糖尿病在内的几种疾病状态相关。该方法继续探索一条新的潜在途径，即通过对人类肠道微生物群组成成分的策略性操纵来干预与肠道微生物群异常变化相关的疾病。
相似文献
1
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of .通过抑制临床相关人类分离株的淀粉利用系统实现非致死性生长抑制 。 （原文句子似乎不完整，“of”后面缺少具体内容）
Medchemcomm. 2019 Jul 5;10(11):1875-1880. doi: 10.1039/c9md00301k. eCollection 2019 Nov 1.
2
Acarbose Impairs Gut Growth by Targeting Intracellular GH97 Enzymes.阿卡波糖通过靶向细胞内GH97酶损害肠道生长。
bioRxiv. 2024 May 23:2024.05.20.595031. doi: 10.1101/2024.05.20.595031.
3
Functional analysis of arginine decarboxylase gene speA of Bacteroides dorei by markerless gene deletion.通过无标记基因缺失对多雷拟杆菌精氨酸脱羧酶基因speA进行功能分析
FEMS Microbiol Lett. 2018 Feb 1;365(4). doi: 10.1093/femsle/fny003.
4
Nonmicrobicidal Small Molecule Inhibition of Polysaccharide Metabolism in Human Gut Microbes: A Potential Therapeutic Avenue.非杀菌性小分子抑制人类肠道微生物多糖代谢：一种潜在的治疗途径。
ACS Chem Biol. 2018 May 18;13(5):1165-1172. doi: 10.1021/acschembio.8b00309. Epub 2018 Apr 20.
5
Exploring the interactive mechanism of acarbose with the amylase SusG in the starch utilization system of the human gut symbiont Bacteroides thetaiotaomicron through molecular modeling.通过分子建模探索阿卡波糖与肠道共生菌拟杆菌属淀粉利用系统中的淀粉酶 SusG 的相互作用机制。
Chem Biol Drug Des. 2023 Sep;102(3):486-499. doi: 10.1111/cbdd.14251. Epub 2023 Apr 16.
6
Effect of Resistant Starch on the Gut Microbiota and Its Metabolites in Patients with Coronary Artery Disease.抗性淀粉对冠心病患者肠道微生物群及其代谢物的影响。
J Atheroscler Thromb. 2019 Aug 1;26(8):705-719. doi: 10.5551/jat.47415. Epub 2018 Dec 27.
7
Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis.脆弱拟杆菌和多形拟杆菌减少肠道微生物脂多糖的产生并抑制动脉粥样硬化。
Circulation. 2018 Nov 27;138(22):2486-2498. doi: 10.1161/CIRCULATIONAHA.118.033714.
8
Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes.多雷拟杆菌在芬兰 1 型糖尿病高危儿童发生自身免疫前主导肠道微生物组。
Front Microbiol. 2014 Dec 10;5:678. doi: 10.3389/fmicb.2014.00678. eCollection 2014.
9
Superresolution imaging captures carbohydrate utilization dynamics in human gut symbionts.超分辨率成像揭示人类肠道共生菌中的碳水化合物利用动态。
mBio. 2014 Nov 11;5(6):e02172. doi: 10.1128/mBio.02172-14.
10
Insights from Species in Children with Type 1 Diabetes.1型糖尿病患儿物种研究见解
Microorganisms. 2021 Jul 2;9(7):1436. doi: 10.3390/microorganisms9071436.
引用本文的文献
1
From background diabetic retinopathy to its proliferative stage. What is the role of gut microbiota in the trajectory of DR? a Mendelian randomization study with mediation analysis.从背景性糖尿病视网膜病变到其增殖期。肠道微生物群在糖尿病视网膜病变病程中起什么作用？一项带有中介分析的孟德尔随机化研究。
Diabetol Metab Syndr. 2025 Aug 20;17(1):346. doi: 10.1186/s13098-025-01813-6.
2
Emerging gut microbial glycoside hydrolase inhibitors.新兴的肠道微生物糖苷水解酶抑制剂
RSC Chem Biol. 2025 Jun 11. doi: 10.1039/d5cb00050e.
3
Acarbose impairs gut growth by targeting intracellular glucosidases.阿卡波糖通过作用于细胞内糖苷酶来损害肠道生长。
mBio. 2024 Dec 11;15(12):e0150624. doi: 10.1128/mbio.01506-24. Epub 2024 Nov 20.
4
Acarbose Impairs Gut Growth by Targeting Intracellular GH97 Enzymes.阿卡波糖通过靶向细胞内GH97酶损害肠道生长。
bioRxiv. 2024 May 23:2024.05.20.595031. doi: 10.1101/2024.05.20.595031.
5
Targeting the human gut microbiome with small-molecule inhibitors.靶向小分子抑制剂的人类肠道微生物组。
Nat Rev Chem. 2023 May;7(5):319-339. doi: 10.1038/s41570-023-00471-4. Epub 2023 Apr 18.
6
Characterizing the Effect of Amylase Inhibitors on Maltodextrin Metabolism by Gut Bacteria Using Fluorescent Glycan Labeling.利用荧光聚糖标记技术研究淀粉酶抑制剂对肠道细菌分解麦芽糊精的影响。
ACS Chem Biol. 2023 Feb 17;18(2):356-366. doi: 10.1021/acschembio.2c00791. Epub 2023 Feb 2.
7
First case of an invasive Bacteroides dorei infection detected in a patient with a mycotic aortic aneurysm-raising a rebellion of major indigenous bacteria in humans: a case report and review.首例侵袭性多雷拟杆菌感染患者的真菌性主动脉瘤——人类主要土著细菌的叛乱：一例病例报告及文献复习。
BMC Infect Dis. 2021 Jun 30;21(1):625. doi: 10.1186/s12879-021-06345-8.
本文引用的文献
1
Current understanding of the role of gut dysbiosis in type 1 diabetes.目前对肠道菌群失调在 1 型糖尿病中作用的认识。
J Diabetes. 2019 Aug;11(8):632-644. doi: 10.1111/1753-0407.12915. Epub 2019 Apr 22.
2
Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study.1 型糖尿病和 MODY2 患儿与健康对照儿童的肠道微生物群在组成和功能上存在差异：一项病例对照研究。
Diabetes Care. 2018 Nov;41(11):2385-2395. doi: 10.2337/dc18-0253. Epub 2018 Sep 17.
3
Gut microbiome in type 1 diabetes: A comprehensive review.1 型糖尿病中的肠道微生物组：全面综述。
Diabetes Metab Res Rev. 2018 Oct;34(7):e3043. doi: 10.1002/dmrr.3043. Epub 2018 Jul 17.
4
Common ground: shared risk factors for type 1 diabetes and celiac disease.共同点：1 型糖尿病和乳糜泻的共同风险因素。
Nat Immunol. 2018 Jul;19(7):685-695. doi: 10.1038/s41590-018-0130-2. Epub 2018 Jun 20.
5
Nonmicrobicidal Small Molecule Inhibition of Polysaccharide Metabolism in Human Gut Microbes: A Potential Therapeutic Avenue.非杀菌性小分子抑制人类肠道微生物多糖代谢：一种潜在的治疗途径。
ACS Chem Biol. 2018 May 18;13(5):1165-1172. doi: 10.1021/acschembio.8b00309. Epub 2018 Apr 20.
6
Gut Microbiota and Type 1 Diabetes.肠道微生物群与 1 型糖尿病。
Int J Mol Sci. 2018 Mar 27;19(4):995. doi: 10.3390/ijms19040995.
7
Structural basis for nutrient acquisition by dominant members of the human gut microbiota.人类肠道微生物群主要成员获取营养的结构基础。
Nature. 2017 Jan 19;541(7637):407-411. doi: 10.1038/nature20828. Epub 2017 Jan 11.
8
The Sus operon: a model system for starch uptake by the human gut Bacteroidetes.Sus操纵子：人类肠道拟杆菌摄取淀粉的模型系统。
Cell Mol Life Sci. 2016 Jul;73(14):2603-17. doi: 10.1007/s00018-016-2242-x. Epub 2016 May 2.
9
Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans.微生物组脂多糖免疫原性的变异导致人类自身免疫。
Cell. 2016 May 5;165(4):842-53. doi: 10.1016/j.cell.2016.04.007. Epub 2016 Apr 28.
10
The role of the intestinal microbiota in type 1 diabetes mellitus.肠道微生物群在 1 型糖尿病中的作用。
Nat Rev Endocrinol. 2016 Mar;12(3):154-67. doi: 10.1038/nrendo.2015.218. Epub 2016 Jan 4.
Zotero 插件